Patents by Inventor Houcong JIN

Houcong JIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
    Patent number: 11780923
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: October 10, 2023
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • ANTI-PD-L1 NANOBODY AND FC FUSION PROTEIN AND APPLICATION THEREOF
    Publication number: 20220242974
    Abstract: Provided are an anti-PD-L1 nanobody and an Fc fusion protein thereof, and an application thereof. The anti-PD-L1 nanobody and the Fc fusion protein thereof have strong specificity, high affinity, and weak immunogenicity to humans. In addition, same have high stability and a significant anti-tumor effect.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 4, 2022
    Inventors: Xiangdong QU, Qin PAN, Houcong JIN, Yejie DU, Han ZHENG
  • ANTI-CLDN ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND DETECTION METHOD THEREFOR
    Publication number: 20220235128
    Abstract: Provided are an anti-CLDN18.2 antibody and a pharmaceutical composition thereof and a detection method therefor, wherein the heavy chain of the antibody is selected from any one of SEQ ID NOs: 1-7 or SEQ ID NOs: 15-30, and the light chain of the antibody is selected from any one of SEQ ID NOs: 8-14 or SEQ ID NOs: 31-46. The ability of the antibody to bind to cell lines and tumor tissue cells is more powerful than that of the existing antibody IMAB362, and the anti-tumor effect of the antibody is also more powerful than that of the existing antibody IMAB362.
    Type: Application
    Filed: April 7, 2020
    Publication date: July 28, 2022
    Inventors: Xiangdong QU, Qin PAN, Houcong JIN, Yejie DU, Han ZHENG
  • PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL APPLICATION THEREOF
    Publication number: 20200399375
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: August 7, 2020
    Publication date: December 24, 2020
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • IL-6R ANTIBODY AND ANTIGEN BINDING FRAGMENT THEREOF AND MEDICAL USE
    Publication number: 20200369774
    Abstract: Provided in the present invention are an IL-6R antibody and antigen-binding fragment thereof. The IL-6R antibody is an alpaca-derived antibody, chimeric antibody and humanized antibody. Also provided in the present invention is the use of the antibody in the preparation of a drug for treating IL-6-related diseases.
    Type: Application
    Filed: September 12, 2018
    Publication date: November 26, 2020
    Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Hua Ying, Houcong Jin, Qiyue Hu, Hu Ge, Yifang Wang, Weikang Tao
  • PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
    Patent number: 10815304
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 27, 2020
    Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Xiangdong Qu, Qiyue Hu, Shaoyu Xu, Dongbing Cui, Houcong Jin, Weikang Tao, Lianshan Zhang, Guoqing Cao, Piaoyang Sun
  • PCSK9 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL USES THEREOF
    Publication number: 20200270365
    Abstract: The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and medical uses thereof.
    Type: Application
    Filed: December 26, 2016
    Publication date: August 27, 2020
    Inventors: Xiangdong QU, Xin YE, Houcong JIN, Dongbing CUI, Qiyue HU, Weikang TAO, Lianshan ZHANG, Piaoyang SUN
  • PD-L1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL APPLICATION THEREOF
    Publication number: 20180334504
    Abstract: The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 22, 2018
    Applicants: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Xiangdong QU, Qiyue HU, Shaoyu XU, Dongbing CUI, Houcong JIN, Weikang TAO, Lianshan ZHANG, Guoqing CAO, Piaoyang SUN